Tiltan Pharma Ltd. announced that it has commenced a Phase 2 clinical trial of its anti-angiogenic product TL-118 for the treatment of pancreatic cancer. Following an approval by the Israeli Ministry of Health, Tiltan Pharma has launched the Phase 2 study in major oncology centers in Israel: The Tel Aviv...
Read more
Monthly Archives: February 2012
Tech Tour Seeks Promising Israeli Medtechs
The European Tech Tour today announced the 2012 Medtech Summit will be held October 16-17 in Lausanne, Switzerland. The Summit works by pairing up and coming European and Israeli start-ups and growth Medtech companies at different stages ranging from Seed to Pre-IPO, with industry players as well as leading cross-border...
Read more
Sol-Gel Raises $27 M
Sol-Gel Technologies Ltd. announced that it has entered into a second development and licensing agreement with a leading U.S. pharmaceutical company for the development and commercialization in the U.S. and Canada of a major dermatologic drug. Under the terms of the new agreement, Sol-Gel will receive $27 million, comprised of...
Read more
Neurology Journal: BrainStorm Stem Cells May Help Huntington’s
BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI) announced that the prestigious Experimental Neurology Journal, published an article indicating that preclinical studies using cells that underwent treatment with Brainstorm’s NurOwn(TM) technology show promise in an animal model of Huntington’s disease. The article was published by leading scientists including Professor Eldad in serum...
Read more